CUE241220C4000
- 0.00
- 0.000.00%
Cue Biopharma Newsroom
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
Cue Biopharma's Nasdaq Compliance Struggle: Risks and Implications for Future Stability
Express News | Cue Biopharma Inc : Jefferies Cuts Target Price to $4 From $6
Stifel Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $4
Stifel Nicolaus Remains a Buy on Cue Biopharma (CUE)
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
Cue Biopharma Reports Q3 EPS (17c), Consensus (19c)
Cue Biopharma | 10-Q: Q3 2024 Earnings Report
Cue Biopharma | 8-K: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Cue Biopharma, Inc. Q3 Operating Expenses USD 12.151 Million
Express News | Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma 3Q Loss/Shr 17c >CUE
Press Release: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Names Daniel Baker Interim CDO, CSO Amish Suri to Transition to Advisor Role
Express News | Cue Biopharma Inc: Daniel Baker Will Join as Interim Chief Development Officer
Express News | Cue Biopharma Announces Strategic Organizational Transition
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $2
Cue Biopharma: Strategic Shift and Promising Clinical Results Support Buy Recommendation